Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice

Neufeld, 2001, The Mucopolysaccharidoses, 3421 Tylki-Szymańska, 2014, Mucopolysaccharidosis type II, Hunter’s syndrome, Pediatr. Endocrinol. Rev., 12, 107 Wilson, 1990, Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA, Proc. Natl. Acad. Sci. USA, 87, 8531, 10.1073/pnas.87.21.8531 Dvorakova, 2017, Genotype-phenotype correlation in 44 Czech, Slovak, Croatian and Serbian patients with mucopolysaccharidosis type II, Clin. Genet., 91, 787, 10.1111/cge.12927 Vollebregt, 2017, Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype, Dev. Med. Child Neurol., 59, 1063, 10.1111/dmcn.13467 Muenzer, 2011, Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey, Genet. Med., 13, 102, 10.1097/GIM.0b013e318206786f Muenzer, 2011, Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome, Genet. Med., 13, 95, 10.1097/GIM.0b013e3181fea459 Pardridge, 1986, Receptor-mediated peptide transport through the blood-brain barrier, Endocr. Rev., 7, 314, 10.1210/edrv-7-3-314 Pardridge, 1987, Human blood-brain barrier transferrin receptor, Metabolism, 36, 892, 10.1016/0026-0495(87)90099-0 Bickel, 2001, Delivery of peptides and proteins through the blood-brain barrier, Adv. Drug Deliv. Rev., 46, 247, 10.1016/S0169-409X(00)00139-3 Pardridge, 2015, Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody, Expert Opin. Drug Deliv., 12, 207, 10.1517/17425247.2014.952627 Osborn, 2008, Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product, Mol. Ther., 16, 1459, 10.1038/mt.2008.119 Zhou, 2012, Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse, Drug Metab. Dispos., 40, 329, 10.1124/dmd.111.042903 Sonoda, 2018, A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II, Mol. Ther., 26, 1366, 10.1016/j.ymthe.2018.02.032 Tanaka, 2018, Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS, Mol. Genet. Metab., 125, 53, 10.1016/j.ymgme.2018.07.013 Okuyama, 2019, Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial, Mol. Ther., 27, 456, 10.1016/j.ymthe.2018.12.005 Okuyama, 2020, A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II, Mol. Ther. Fujitsuka, 2019, Biomarkers in patients with mucopolysaccharidosis type II and IV, Mol. Genet. Metab. Rep., 19, 100455, 10.1016/j.ymgmr.2019.100455 Bigger, 2018, Anatomical changes and pathophysiology of the brain in mucopolysaccharidosis disorders, Mol. Genet. Metab., 125, 322, 10.1016/j.ymgme.2018.08.003 Tomatsu, 2014, Establishment of glycosaminoglycan assays for mucopolysaccharidoses, Metabolites, 4, 655, 10.3390/metabo4030655 Węgrzyn, 2010, Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?, Med. Hypotheses, 75, 605, 10.1016/j.mehy.2010.07.044 Sato, 2020, Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses, Int. J. Mol. Sci., 21, 400, 10.3390/ijms21020400 Valayannopoulos, 2010, Mucopolysaccharidosis VI, Orphanet J. Rare Dis., 5, 5, 10.1186/1750-1172-5-5 Shapiro, 2017, Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms, Mol. Genet. Metab., 122S, 1, 10.1016/j.ymgme.2017.08.009 Węgrzyn, 2018, Mechanisms of neurodegeneration in mucopolysaccharidoses, 87 Sharma, 2018, Lysosomes and Brain Health, Annu. Rev. Neurosci., 41, 255, 10.1146/annurev-neuro-080317-061804 Fusar Poli, 2013, Murine neural stem cells model Hunter disease in vitro: glial cell-mediated neurodegeneration as a possible mechanism involved, Cell Death Dis., 4, e906, 10.1038/cddis.2013.430 Zalfa, 2016, Glial degeneration with oxidative damage drives neuronal demise in MPSII disease, Cell Death Dis., 7, e2331, 10.1038/cddis.2016.231 Meikle, 1997, Diagnosis of lysosomal storage disorders: evaluation of lysosome-associated membrane protein LAMP-1 as a diagnostic marker, Clin. Chem., 43, 1325, 10.1093/clinchem/43.8.1325 Kondagari, 2015, The effects of intracisternal enzyme replacement versus sham treatment on central neuropathology in preclinical canine fucosidosis, Orphanet J. Rare Dis., 10, 143, 10.1186/s13023-015-0357-z Wolf, 2016, A mouse model for fucosidosis recapitulates storage pathology and neurological features of the milder form of the human disease, Dis. Model. Mech., 9, 1015 D’Hooge, 2001, Applications of the Morris water maze in the study of learning and memory, Brain Res. Brain Res. Rev., 36, 60, 10.1016/S0165-0173(01)00067-4 Fu, 2018, Targeting Root Cause by Systemic scAAV9-hIDS Gene Delivery: Functional Correction and Reversal of Severe MPS II in Mice, Mol. Ther. Methods Clin. Dev., 10, 327, 10.1016/j.omtm.2018.07.005 Sharma, 2010, Assessment of spatial memory in mice, Life Sci., 87, 521, 10.1016/j.lfs.2010.09.004 Vorhees, 2014, Assessing spatial learning and memory in rodents, ILAR J., 55, 310, 10.1093/ilar/ilu013 Muenzer, 2016, A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II, Genet. Med., 18, 73, 10.1038/gim.2015.36 Calias, 2012, CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder, PLoS ONE, 7, e30341, 10.1371/journal.pone.0030341 Higuchi, 2012, Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II, Mol. Genet. Metab., 107, 122, 10.1016/j.ymgme.2012.05.005